Loading...
Integrated strategy for the production of therapeutic retroviral vectors.
Carrondo, Manuel Panet, Amos Wirth, Dagmar Coroadinha, Ana Sofia Cruz, Pedro Falk, Haya Schucht, Roland Dupont, Francis Geny-Fiamma, Cécile Merten, Otto-Wilhelm
Carrondo, Manuel
Panet, Amos
Wirth, Dagmar
Coroadinha, Ana Sofia
Cruz, Pedro
Falk, Haya
Schucht, Roland
Dupont, Francis
Geny-Fiamma, Cécile
Merten, Otto-Wilhelm
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2011-03
Submitted date
Files
Loading...
Allowed publisher's PDF
Adobe PDF, 1.56 MB
Other Titles
Abstract
The broad application of retroviral vectors for gene delivery is still hampered by the difficulty to reproducibly establish high vector producer cell lines generating sufficient amounts of highly concentrated virus vector preparations of high quality. To enhance the process for producing clinically relevant retroviral vector preparations for therapeutic applications, we have integrated novel and state-of-the-art technologies in a process that allows rapid access to high-efficiency vector-producing cells and consistent production, purification, and storage of retroviral vectors. The process has been designed for various types of retroviral vectors for clinical application and to support a high-throughput process. New modular helper cell lines that permit rapid insertion of DNA encoding the therapeutic vector of interest at predetermined, optimal chromosomal loci were developed to facilitate stable and high vector production levels. Packaging cell lines, cultivation methods, and improved medium composition were coupled with vector purification and storage process strategies that yield maximal vector infectivity and stability. To facilitate GMP-grade vector production, standard of operation protocols were established. These processes were validated by production of retroviral vector lots that drive the expression of type VII collagen (Col7) for the treatment of a skin genetic disease, dystrophic epidermolysis bullosa. The potential efficacy of the Col7-expressing vectors was finally proven with newly developed systems, in particular in target primary keratinocyte cultures and three-dimensional skin tissues in organ culture.
Citation
Integrated strategy for the production of therapeutic retroviral vectors. 2011, 22 (3):370-9 Hum. Gene Ther.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1557-7422